These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8166466)

  • 1. Small cell lung cancer and topoisomerases.
    Giaccone G
    Anticancer Res; 1994; 14(1B):269-76. PubMed ID: 8166466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerases and topoisomerase inhibitors.
    Giaccone G
    Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
    Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer].
    Guo QS; Liu YX; Yu JM; Wang JL; Zhong WX; Liu XJ
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):124-6. PubMed ID: 17645849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
    Funayama Y; Nishio K; Takeda Y; Kubota N; Ohira T; Ohmori T; Ohta S; Ogasawara H; Hasegawa S; Saijo N
    Anticancer Res; 1993; 13(6A):1981-8. PubMed ID: 8297104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
    Yu Q; Mirski SE; Sparks KE; Cole SP
    Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma.
    Shuin T; Sano K
    Anticancer Res; 1994; 14(6B):2621-6. PubMed ID: 7872691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I.
    Hasegawa T; Isobe K; Nakashima I; Shimokata K
    Biochem Biophys Res Commun; 1993 Aug; 195(1):409-14. PubMed ID: 8395833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerases: from a laboratory curiosity to a subject in cancer chemotherapy.
    Wang JC
    NCI Monogr; 1987; (4):3-6. PubMed ID: 2819727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DNA supercoiling and topoisomerases in Escherichia coli].
    Gómez-Eichelmann MC; Camacho-Carranza R
    Rev Latinoam Microbiol; 1995; 37(3):291-304. PubMed ID: 8850348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
    Boege F
    Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
    Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
    Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistance related genes and p53 expression in human non small cell lung cancer.
    Galimberti S; Marchetti A; Buttitta F; Carnicelli V; Pellegrini S; Bevilacqua G; Petrini M
    Anticancer Res; 1998; 18(4C):2973-6. PubMed ID: 9713494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
    Withoff S; De Jong S; De Vries EG; Mulder NH
    Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
    Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
    Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
    Bence AK; Mattingly CA; Burke TG; Adams VR
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):354-60. PubMed ID: 15197485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.